Streetbeat News

Products Services

MRK

Merck & Co Inc (NYSE:MRK) reported that Keytruda, its cancer drug, showed a significant improvement in disease-free survival for patients with advanced bladder cancer post-surgery in the Phase 3 AMBASSADOR/KEYNOTE-123 trial. The data, presented at the ASCO GU Symposium, indicated a 31% reduction in disease recurrence or death risk compared to observation. Median DFS was 29.0 months for Keytruda versus 14.0 months for observation. The overall survival endpoint has not yet reached statistical significance. Keytruda's safety profile remained consistent with no new safety signals. MRK shares rose 0.53% to $120.77.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 8:14 pm

CRBP

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) stock is trading higher after announcing promising data from a Phase 1 clinical study of CRB-701 (SYS6002) at the American Society of Clinical Oncology Genitourinary Cancers Symposium. The study targets metastatic urothelial cancer and other nectin-4 positive tumors, showing a 43% objective response rate and a 71% disease control rate at higher doses. CRB-701 demonstrated lower toxicity compared to enfortumab vedotin, with no severe adverse events or cases of drug-related peripheral neuropathy or skin rash reported. CRBP shares surged 257.80% to $30.20.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 8:05 pm

ETH-USD

The Ethereum Foundation has announced the final timeline for the Dencun network upgrade, with activations on the Goerli testnet completed and upcoming activations on the Sepolia and Holesky testnets. Dencun is a major upgrade for Ethereum, introducing improvements like EIP-4844 to reduce transaction fees on Layer 2 solutions. The upgrade includes several EIPs and requires node operators and stakers on the testnets to update their clients. The successful deployment on testnets will lead to activation on the Ethereum mainnet, potentially enhancing transaction efficiency and network performance.

Portfolio Pulse from Murtuza Merchant

January 26, 2024 | 7:42 pm

ADBE

CRM

DOCU

NVDA

QQQ

The article discusses the recent tech rally, highlighting the performance of the QQQ index and Nvidia (NVDA). It suggests looking at other tech stocks like Salesforce (CRM) and Adobe (ADBE), which have also seen significant gains and are approaching all-time highs. Salesforce received an analyst upgrade and may raise subscription prices in 2024. Adobe's growth is outpacing DocuSign (DOCU), and both CRM and ADBE have potential to test new highs according to their chart setups.

Portfolio Pulse from Thrash Capital

January 26, 2024 | 7:34 pm

ABNB

BTIG analyst reports that Airbnb is set to raise guest fees on cross-currency transactions beginning in April. This change could affect the booking costs for users who are paying in a different currency than the listing's price.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:27 pm

CALT

VERA

Vera Therapeutics Inc (NASDAQ:VERA) stock surged nearly 50% after positive 72-week data from a Phase 2b trial of atacicept for IgA nephropathy (IgAN). Analysts responded with rating upgrades and increased price targets. Oppenheimer initiated coverage with an Outperform rating and a $26 target. Raymond James upgraded to Strong Buy and raised their target from $29 to $37. Wedbush maintained a Neutral rating but increased their target from $16 to $21. The stock's volume significantly exceeded the average. Calliditas Therapeutics AB (NASDAQ:CALT), which also develops IgAN treatments, had its drug Tarpeyo approved by the FDA in December.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 7:13 pm

BTC-USD

A crypto expert has provided a guide on tokenomics, explaining how to value tokens by analyzing supply, demand, and utility. Key factors include total supply, inflation rate, and utility in driving demand. The guide also covers token allocation, unlocking schedules, and the balance between yields, inflation, and lockup periods. Understanding the supply structure, whether capped or unlimited, is crucial for long-term value assessment. These insights are vital for investors in the evolving cryptocurrency market.

Portfolio Pulse from Murtuza Merchant

January 26, 2024 | 7:00 pm

ACON

ATEC

Aclarion Inc (NASDAQ:ACON) stock surged on high volume without specific news. Last week, Aclarion released Nociscan 2.6, supporting more MRI scanners. Earlier, Aclarion and Alphatec Holdings, Inc. (NASDAQ:ATEC) solidified a partnership, boosting ACON shares by over 60%. Aclarion also underwent a 1-for-16 reverse stock split in January.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 6:48 pm

SPY

Commerce Secretary Raimondo announced that the U.S. will propose rules for cloud companies regarding reporting requirements. The rule focuses on identifying users of U.S. cloud services for AI model training.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 6:45 pm

SPCE

Virgin Galactic announced the completion of its first spaceflight of 2024, 'Galactic 06', marking its 11th mission. This flight was notable for having all four seats on VSS Unity occupied by private astronauts for the first time.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 6:43 pm